Braveheart Bio, Inc. AI Stock Analysis
Braveheart Bio, Inc. (BRVE) AI Stock Analysis
Braveheart Bio, Inc.
(NASDAQ:BRVE)
No summary available
Braveheart Bio, Inc. (BRVE) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.33B
- Dividend Yield
- ―
- Average Volume (3M)
- 460.31K
- Price to Earnings (P/E)
- -6.4
- Beta (1Y)
- -0.04
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 49
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Braveheart Bio, Inc. Business Overview & Revenue Model
Company Description
Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquarter...
Braveheart Bio, Inc. Peers Comparison
Overall Rating
ANAB61Neutral
XNCR61Neutral
ZBIO51Neutral
NUVB49Neutral
ZYME48Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 61Neutral | $1.36B | 7.14 | 906.99% | ― | 13.04% | ― | |
| 61Neutral | $2.59B | -22.05 | -21.29% | ― | 33.55% | 11.51% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 51Neutral | $1.88B | -2.76 | -208.91% | ― | -26.67% | -121.60% | |
| 49Neutral | $1.38B | -9.91 | -49.11% | ― | 654.19% | 39.07% | |
| 48Neutral | $1.80B | 38.32 | 22.48% | ― | 97.78% | ― |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| BRVE | Braveheart Bio, Inc. | 18.53 | -11.27 | -37.82% | |
| XNCR | Xencor Inc. | 34.39 | 18.82 | 120.80% | |
| ANAB | AnaptysBio | 47.06 | 21.96 | 87.48% | |
| ZYME | Zymeworks | 26.04 | 2.22 | 9.32% | |
| NUVB | Nuvation Bio Inc | 3.78 | -3.23 | -46.08% | |
| ZBIO | Zenas BioPharma, Inc. | 26.42 | -8.42 | -24.17% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
